Astex Pharmaceuticals Inc. / Cancer Research Technology / The Institute of Cancer / Clinical Development Partnerships / The Royal Marsden Hospital / Astex Pharmaceuticals Astex Pharmaceuticals / Cancer Research UK / Astex Pharmaceuticals / /
Continent
Europe / /
Country
United States / Canada / United Kingdom / /
Event
FDA Phase / Business Partnership / /
Facility
About The Institute of Cancer Research / Cancer Therapeutics Unit The Institute of Cancer Research's Cancer Research / The Institute of Cancer Research / www.icr.ac.uk About The Institute of Cancer Research's Cancer Research / University of London / /
IndustryTerm
owned subsidiary / Cancer Therapeutics / cancer treatment / pharmaceutical / treatment of cancer / treatment for brain cancer / /
MedicalCondition
PI3K - AKT tumor / influential cancer / advanced prostate cancer / Cancer / genetic disease / top four cancer / international cancer / personalized cancer / brain cancer / /
MedicalTreatment
cancer therapeutics / /
Organization
Institute of Cancer Research's Cancer Research UK Cancer Therapeutics Unit / Royal Marsden Hospital / Drug Development Office / University of London / Cancer Research UK's Drug Development Office / /
Person
Victoria John / Harren Jhoti / /
Position
head of clinical partnerships / president and director / /
Product
Temozolomide / DACOGEN / Drug / one drug / PKB drug / /
January 16, 2013 Cancer Research UK and Cancer Research Technology Initiate AT13148 Clinical Trial to Treat Several Cancer Types DUBLIN, Calif., Jan. 16, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX